Abstract: Lupus nephritis (LN) is a complication of systemic lupus erythematosus (SLE) with high incidence. Its pathogenesis has not yet been fully elucidated. It is mainly treated with glucocorticoids and classic immunosuppressive agents. The use of these drugs can cause a series of related complications, which makes the LN treatment become more difficult. The role of B cells in SLE/LN has been widely recognized, and biological agents targeting different targets of B cells have been developed to provide a new direction for the treatment of LN. This article reviews the role of B cells in LN and the progress of related biological agents in the treatment of LN.